Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGKA | P23743 | 1/20 | 0.69 |
| ▸ | PAM | P19021 | 2/20 | 0.62 |
| ▸ | TSHR | P16473 | 2/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 4/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | PRKCA | P17252 | 1/20 | 0.51 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.51 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.51 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.51 |
| ▸ | CES2 | O00748 | 3/20 | 0.50 |
| ▸ | CES1 | P23141 | 3/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1782819 | 1.00 | DGKA (0.69) | DGKAPAMTSHRMAPTLMNA | |
| SCHEMBL29366771 | 1.00 | DGKA (0.69) | DGKAPAMTSHRMAPTLMNA | |
| SCHEMBL10901771 | 1.00 | DGKA (0.69) | DGKAPAMTSHRMAPTLMNA | |
| SCHEMBL2857061 | 1.00 | DGKA (0.69) | DGKAPAMTSHRMAPTLMNA | |
| SCHEMBL28699910 | 1.00 | DGKA (0.69) | DGKAPAMTSHRMAPTLMNA | |
| SCHEMBL355177 | 1.00 | DGKA (0.69) | DGKAPAMTSHRMAPTLMNA | |
| SCHEMBL6266491 | 1.00 | DGKA (0.69) | DGKAPAMTSHRMAPTLMNA | |
| SCHEMBL10414846 | 1.00 | DGKA (0.69) | DGKAPAMTSHRMAPTLMNA | |
| SCHEMBL356145 | 1.00 | DGKA (0.69) | DGKAPAMTSHRMAPTLMNA | |
| Heptanoic Acid Chloromethyl Ester SCHEMBL697729 | 1.00 | DGKA (0.69) | DGKAPAMTSHRMAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 109 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122070276-A | Prodrugs of xanomeline, prodrugs of trospium chloride and methods of using the same | 人类生物科学股份有限公司 | 2026-05-19 | — | — | CN | disclosed |
| CN-122055369-A | Bridged tricyclic carbamoyl pyridone compounds and uses thereof | 吉利德科学公司 | 2026-05-15 | — | — | CN | disclosed |
| EP-4705289-A1 | PRODRUGS OF XANOMELINE, PRODRUGS OF TROSPIUM AND METHODS OF USE THEREOF | Terran Biosciences Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| US-12570605-B2 | Indole compounds, and preparation methods, and uses thereof | SHENZHEN 01 LIFE SCIENCE AND TECHNOLOGY CO., LTD. (CN) | 2026-03-10 | — | — | US | disclosed |
| WO-2025080863-A1 | BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2025-04-17 | — | — | WO | disclosed |
| US-20250122219-A1 | BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. | 2025-04-17 | — | — | US | disclosed |
| US-12269818-B2 | Analogs of xanomeline | TERRAN BIOSCIENCES INC. (US) | 2025-04-08 | — | — | US | disclosed |
| US-20250066376-A1 | OPIOID RECEPTOR ANTAGONIST PRODRUGS | NIRSUM LABORATORIES INC (US) | 2025-02-27 | — | — | US | disclosed |
| US-20240368149-A1 | ANALOGS OF XANOMELINE | TERRAN BIOSCIENCES INC. | 2024-11-07 | — | — | US | disclosed |
| CN-115677718-B | Methyl methylamine derivative preparation, pharmaceutical composition and application thereof | 武汉思瓴生物科技有限公司 | 2024-11-01 | — | — | CN | disclosed |
| EP-0147177-B1 | ETHER PRODRUGS OF ANTI-INFLAMMATORY OXICAMS | PFIZER INC. (US) | 1987-10-14 | — | — | EP | disclosed |
| EP-0219451-A1 | Semicarbazones and thiosemicarbazones | SANDOZ AG (CH) | 1987-04-22 | — | — | EP | disclosed |
| US-4567034-A | Esters of diatrizoic acid as X-ray contrast agents | E. R. SQUIBB & SONS, INC. (US) | 1986-01-28 | — | — | US | disclosed |
| US-4551452-A | Anti-inflammatory 2-methyl-2H-1,2-benzo-(or -thieno-)thiazine-3-carboxamide 1,1-dioxide derivatives, compositions, and method of use therefor | PFIZER INC. (US) | 1985-11-05 | — | — | US | disclosed |
| EP-0147177-A2 | Ether prodrugs of anti-inflammatory oxicams | PFIZER INC. (US) | 1985-07-03 | — | — | EP | disclosed |
| US-4313889-A | Soft quaternary surface active agents | MERCK & CO., INC. (US) | 1982-02-02 | — | — | US | disclosed |
| US-4267326-A | AS ANTITUMOR AGENTS | MITSUI TOATSU CHEMICALS, INCORPORATED (JP) | 1981-05-12 | — | — | US | disclosed |
| US-4204065-A | Soft quaternary surface active agents and method of using same | INTERX RESEARCH CORPORATION (US) | 1980-05-20 | — | — | US | disclosed |
| US-4160099-A | Labile, non-heterocyclic quaternary ammonium salt/esters as transient derivatives | INTERX RESEARCH CORPORATION | 1979-07-03 | — | — | US | disclosed |
| US-3989711-A | Soft quaternary surface active agents exhibiting antibacterial activity | INTERX RESEARCH CORPORATION (US) | 1976-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250066376-A1 | OPIOID RECEPTOR ANTAGONIST PRODRUGS | OPRL1, OPRM1, OPRD1 | DGKA 3915/4885PAM 68/4885TSHR 209/4885 |
| US-20250122219-A1 | BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND USES THEREOF | SDHA, SDHB, DPYD | DGKA 2770/4885PAM 3580/4885TSHR 4706/4885 |
| US-20240368149-A1 | ANALOGS OF XANOMELINE | HTR5A, HTR3A, HTR3B | DGKA 2991/4885PAM 1063/4885TSHR 399/4885 |
| US-12269818-B2 | Analogs of xanomeline | HTR5A, HTR3A, HTR3B | DGKA 2991/4885PAM 1063/4885TSHR 399/4885 |
| US-12570605-B2 | Indole compounds, and preparation methods, and uses thereof | IDO2, IDO1, TPH2 | DGKA 2440/4885PAM 3927/4885TSHR 1333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.